Diversify Wealth Management LLC Grows Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Diversify Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 160.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,773 shares of the pharmaceutical company's stock after purchasing an additional 6,027 shares during the quarter. Diversify Wealth Management LLC's holdings in Vertex Pharmaceuticals were worth $4,002,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in VRTX. Czech National Bank raised its stake in shares of Vertex Pharmaceuticals by 6.2% during the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company's stock worth $22,486,000 after buying an additional 3,260 shares during the period. Whalen Wealth Management Inc. acquired a new position in Vertex Pharmaceuticals during the third quarter worth $662,000. Creative Planning grew its position in shares of Vertex Pharmaceuticals by 5.3% in the second quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company's stock valued at $37,084,000 after purchasing an additional 3,998 shares in the last quarter. Mizuho Securities USA LLC increased its holdings in shares of Vertex Pharmaceuticals by 289.0% in the third quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company's stock valued at $35,994,000 after purchasing an additional 57,497 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in Vertex Pharmaceuticals by 19.4% during the fourth quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company's stock worth $137,783,000 after buying an additional 55,739 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of recent research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Canaccord Genuity Group lifted their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a "sell" rating in a research note on Wednesday, November 6th. StockNews.com cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 21st. BMO Capital Markets decreased their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating on the stock in a report on Friday, December 20th. Finally, Stifel Nicolaus raised their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a research note on Monday, December 16th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $490.38.

Vertex Pharmaceuticals Stock Up 1.2 %

NASDAQ:VRTX traded up $5.04 during mid-day trading on Monday, hitting $422.00. The stock had a trading volume of 1,771,827 shares, compared to its average volume of 1,811,179. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The stock has a 50-day simple moving average of $440.94 and a two-hundred day simple moving average of $466.06. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $108.68 billion, a PE ratio of -212.06, a PEG ratio of 2.11 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company's quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.67 EPS. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.